Delayed anticoagulation in venous thromboembolism: Reasons and associated outcomes

被引:4
作者
Brunton, Nichole E. [1 ]
Wysokinski, Waldemar E. [2 ]
Hodge, David O. [3 ]
Vlazny, Danielle T. [2 ]
Houghton, Damon E. [2 ]
Casanegra, Ana I. [2 ]
机构
[1] Danbury Hosp, Dept Internal Med, Danbury, CT USA
[2] Mayo Clin, Gonda Vasc Ctr, Div Vasc Med, Dept Cardiovasc Med, Rochester, MN USA
[3] Mayo Clin, Dept Hlth Sci Res, Jacksonville, FL 32224 USA
关键词
anticoagulant; neoplasm; recurrence; registry; time to treatment; venous thromboembolism; ANTITHROMBOTIC THERAPY; PULMONARY-EMBOLISM; TREATMENT PATTERNS; VTE; DISEASE; THROMBOSIS; POPULATION; DEFINITION; PREDICTORS; MANAGEMENT;
D O I
10.1002/rth2.12500
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: We assessed the number of cases with delayed anticoagulation initiation, explored the reasons for the delay, and its impact on outcome in patients with acute venous thromboembolism (VTE) treated in an organized setting of treatment initiation and continuous, prospective follow-up. Methods: Patients with anticoagulation initiation delay >24 hours were identified within the cohort of patients with acute VTE enrolled in the Mayo Clinic Venous Thromboembolism Registry between 2013 and 2020. The reasons for treatment delay were explored by reviewing the electronic database. VTE recurrence, all-cause mortality, major bleeding, and clinically relevant nonmajor bleeding (CRNMB) were compared to those with no anticoagulation delay. Results: Of 2378 patients with acute VTE, 100 (4.2%) experienced an anticoagulation delay. We identified seven reasons for treatment delays: deferring anticoagulation initiation to specialists (n = 38), thrombocytopenia (n = 10), planned or recent procedure (n = 16), active or recent bleeding (n = 12), missed diagnosis (n = 7), logistics (n = 6), and patient decision (n = 4). In seven cases, no reason was identified. We identified modifiable reasons for anticoagulation delay in 55%. At 90-day follow-up, patients with anticoagulation delay had a higher rate of mortality and major bleeding. VTE recurrence and CRNMB were not statistically different compared to those without anticoagulation delay. After adjustment for age, weight, and cancer, hazard ratios (HRs) for VTE recurrence and major bleeding remained elevated but not to a statistically significant level. Conclusion: In the setting of a highly organized system of anticoagulation initiation, the incidence of treatment delay is low. Yet most delays could be avoided. A low number of cases provide insufficient power to evaluate the clinical consequences of anticoagulation initiation delay; however, elevated HR for VTE recurrence and major bleeding suggest association and need for further investigation.
引用
收藏
页数:8
相关论文
共 22 条
  • [1] Oral Apixaban for the Treatment of Acute Venous Thromboembolism
    Agnelli, Giancarlo
    Buller, Harry R.
    Cohen, Alexander
    Curto, Madelyn
    Gallus, Alexander S.
    Johnson, Margot
    Masiukiewicz, Urszula
    Pak, Raphael
    Thompson, John
    Raskob, Gary E.
    Weitz, Jeffrey I.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (09) : 799 - 808
  • [2] Predictors of Not Initiating Anticoagulation After Incident Venous Thromboembolism: A Danish Nationwide Cohort Study
    Albertsen, Ida Ehlers
    Goldhaber, Samuel Zachary
    Piazza, Gregory
    Overvad, Thure Filskov
    Nielsen, Peter Bronnum
    Larsen, Torben Bjerregaard
    Sogaard, Mette
    [J]. AMERICAN JOURNAL OF MEDICINE, 2020, 133 (04) : 463 - +
  • [3] Apixaban and Rivaroxaban in Patients With Acute Venous Thromboembolism
    Bott-Kitslaar, Dalene M.
    McBane, Robert D.
    Casanegra, Ana I.
    Houghton, Damon E.
    Froehling, David A.
    Vlazny, Danielle T.
    Ashrani, Aneel A.
    Hodge, David O.
    Vargas, Emily R.
    Bartlett, Matthew A.
    Saadiq, Rayya A.
    Daniels, Paul R.
    Shields, Raymond C.
    Lenz, Charles J.
    Lang, Teresa R.
    Wysokinski, Waldemar E.
    [J]. MAYO CLINIC PROCEEDINGS, 2019, 94 (07) : 1242 - 1252
  • [4] Vascular Disorders of the Liver
    DeLeve, Laurie D.
    Valla, Dominique-Charles
    Garcia-Tsao, Guadalupe
    [J]. HEPATOLOGY, 2009, 49 (05) : 1729 - 1764
  • [5] Determinants and prognostic implication of diagnostic delay in patients with a first episode of pulmonary embolism
    Goyard, Celine
    Cote, Benoit
    Looten, Vincent
    Roche, Anne
    Pastre, Jean
    Marey, Jonathan
    Planquette, Benjamin
    Meyer, Guy
    Sanchez, Olivier
    [J]. THROMBOSIS RESEARCH, 2018, 171 : 190 - 198
  • [6] Predictors of recurrence after deep vein thrombosis and pulmonary embolism -: A population-based cohort study
    Heit, JA
    Mohr, DN
    Silverstein, MD
    Petterson, TM
    O'Fallon, WM
    Melton, LJ
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (06) : 761 - 768
  • [7] Rivaroxaban and Apixaban for Initial Treatment of Acute Venous Thromboembolism of Atypical Location
    Janczak, Dawid T.
    Mimier, Malgorzata K.
    McBane, Robert D.
    Kamath, Patrick S.
    Simmons, Benjamin S.
    Bott-Kitslaar, Dalene M.
    Lenz, Charles J.
    Vargas, Emily R.
    Hodge, David O.
    Wysokinski, Waldemar E.
    [J]. MAYO CLINIC PROCEEDINGS, 2018, 93 (01) : 40 - 47
  • [8] Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH
    Kaatz, S.
    Ahmad, D.
    Spyropoulos, A. C.
    Schulman, S.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 (11) : 2119 - 2126
  • [9] Management and adherence to VTE treatment guidelines in a national prospective cohort study in the Canadian outpatient setting The Recovery Study
    Kahn, Susan R.
    Springmann, Vicky
    Schulman, Sam
    Martineau, Josee
    Stewart, John A.
    Komari, Nelly
    McLeod, Anne
    Strulovitch, Carla
    Blostein, Mark
    Faucher, Jacques-Philippe
    Gamble, Greg
    Gordon, Wendy
    Kagoma, Peter K.
    Miron, Marie-Jose
    Laverdiere, David
    Game, Melaku
    Mills, Allan
    [J]. THROMBOSIS AND HAEMOSTASIS, 2012, 108 (03) : 493 - 498
  • [10] Antithrombotic Therapy for VTE Disease CHEST Guideline and Expert Panel Report
    Kearon, Clive
    Akl, Elie A.
    Ornelas, Joseph
    Blaivas, Allen
    Jimenez, David
    Bounameaux, Henri
    Huisman, Menno
    King, Christopher S.
    Morris, Timothy A.
    Sood, Namita
    Stevens, Scott M.
    Vintch, Janine R. E.
    Wells, Philip
    Woller, Scott C.
    Moores, Lisa
    [J]. CHEST, 2016, 149 (02) : 315 - 352